Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2024-03-15 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
健民集团董事会审计委员会关于对中审众环2023年年度审计工作的监督与评价报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Board Audit Committee regarding the supervision and evaluation of the external auditor's work for the fiscal year 2023. It discusses the auditor's qualifications, the audit process, communication with auditors, and the audit results including financial statements and internal control effectiveness. It does not contain the full annual report or financial statements themselves but is a supervisory report on the audit work performed. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of audit supervision, distinct from the full Annual Report (10-K). The document length is 2270 characters, which is relatively short but contains substantive content about the audit process and evaluation, not just an announcement or certification. Therefore, the classification is AR with high confidence. FY 2023
2024-03-15 Chinese
健民集团关于召开2023年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a notice about the convening of the 2023 Annual General Meeting (AGM) of the company, including details such as the date, voting methods, agenda items, and instructions for shareholders. It does not contain the actual annual report or financial statements but rather information about the meeting where such reports will be discussed and voted on. The document length is 3281 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2024-03-15 Chinese
健民集团第十届监事会第九次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 健民药业集团股份有限公司 regarding several agenda items including the 2023 Supervisory Board work report, the 2023 Annual Report, profit distribution plan, financial budget, internal control evaluation report, and amendments to meeting rules. It states that these items will be submitted to the shareholders' meeting for approval. The document references the availability of the full 2023 Annual Report and other reports on official websites but does not contain the reports themselves. The document length is short (1271 characters) and serves as an announcement of meeting resolutions and voting results rather than the full reports or detailed financial data. Therefore, it fits best as a Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-03-15 Chinese
健民集团关于2024年融资额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the board of directors regarding the company's financing credit limit for the year 2024. It details the proposed credit limit, the types of credit facilities, the authorization for management to handle financing matters, and the necessity of the credit limit for business operations. There are no financial statements or detailed financial performance data included. The document is focused on financing activities and credit arrangements rather than reporting financial results or other report types. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and it is not merely announcing the publication of a report, so it is not RPA or RNS. Hence, the classification is CAP with high confidence.
2024-03-15 Chinese
健民集团关于2024年对外捐赠的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding a charitable donation of 2 million yuan to a registered public welfare foundation. It details the donation amount, recipient, purpose, and terms of the donation. There is no financial report, earnings data, management discussion, or regulatory filing content. The document is a formal announcement of a corporate social responsibility action, not a financial or regulatory report. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is a general regulatory announcement about a corporate donation, which fits best under Regulatory Filings (RNS) as a miscellaneous corporate announcement that does not fit other specific categories.
2024-03-15 Chinese
健民药业集团股份有限公司郭云沛独立董事2023年述职报告
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of a company, describing their duties, attendance at meetings, oversight of audits, involvement in governance, and communication with shareholders during the year 2023. It includes extensive information on board activities, audit work, related party transactions, guarantees, capital usage, remuneration, and internal controls. The document is lengthy (6875 characters) and contains substantive content about the director's role and company governance over the year, rather than being a brief announcement or certification. This fits the category of Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management activities. It is not an Annual Report (10-K) or Audit Report (AR) because it focuses on the independent director's report and board activities rather than full financial statements or audit opinions. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains detailed substantive content rather than a short notice. Therefore, the best classification is MANG with high confidence.
2024-03-15 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.